Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$32.2B
144M shares
52-week range
$180.27 – $284.87
47% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
P/S (TTM)
5.9
EV / FCF (TTM)
11.3
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
www.resmed.comNo one on the platform currently holds RMD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 304,480 | $73.3M |
| Bridgewater Associatesas of 2026-03-31 | 39,237 | $8.8M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-20 | $0.6600 | 2026-09-24 |
| 2026-05-14 | $0.6000 | 2026-06-18 |
| 2026-02-12 | $0.6000 | 2026-03-19 |
| 2025-11-13 | $0.6000 | 2025-12-18 |
| 2025-08-14 | $0.6000 | 2025-09-18 |
| 2025-05-08 | $0.5300 | 2025-06-12 |
| 2025-02-13 | $0.5300 | 2025-03-20 |
| 2024-11-07 | $0.5300 | 2024-12-12 |
| 2024-08-15 | $0.5300 | 2024-09-19 |
| 2024-05-08 | $0.4800 | 2024-06-13 |
No one on the platform has traded RMD yet.
| 2024-02-07 | $0.4800 | 2024-03-14 |
| 2023-11-08 | $0.4800 | 2023-12-14 |
| Execution date | Ratio |
|---|---|
| 2010-08-31 | 2-for-1 |
| 2005-10-03 | 2-for-1 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 25.3% | 21.4% | 18.7% | — | — | — |
| Rev. Growth % | 9.9% | 12.1% | ||||
| Profit Margin % | 26.9% | 23.8% | 20.0% | |||
| Free Cash Flow Margin % | 29.2% | 21.5% | 20.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +1.9% on the P/E track.
At today's price, your expected annual return is +7.3% on the P/E track.
At today's price, your expected annual return is +12.6% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $5.8B | +2.8% | $12.09 | $11.81–$12.32 | 19.0× | 14 |
| 2028 | $6.2B | +6.5% | $13.30 | $13.13–$13.69 | 17.3× | 14 |
| 2029 | $6.6B | +6.5% | $14.51 | $12.88–$15.21 | 15.8× | 7 |
| 2030 | $7.1B | +7.3% | $15.69 | $15.06–$16.51 | 14.6× | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $2.89 | $2.95 | +2.1% |
| 2026-04-30 | $2.80 | $2.86 | +2.1% |
| 2026-01-29 | $2.74 | $2.81 | +2.6% |
| 2025-10-30 | $2.51 | $2.55 | +1.6% |
| 2025-07-31 | $2.46 | $2.55 | +3.7% |
| 2025-04-23 | $2.38 | $2.37 | -0.4% |
| 2025-01-30 | $2.32 | $2.43 | +4.7% |
| 2024-10-24 | $2.04 |
| $2.20 |
| +7.8% |
| $54.5B |
| — |
| GEHCGE HealthCare Technologies Inc. | $64.07 | -0.28% | $28.9B | — |
| HLNHaleon plc | $9.24 | -1.60% | $40.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$RMD (ResMed) advances nearly 5% Tuesday after RBC Capital upgraded the medical device and digital health company, even as the broader market fell for a second straight day ahead of the Fed's rate decision.
View on StockTwits ↗
$AMD i love a good coincidence. Yesterday i had an appt to go over results of a sleep study. It was determined I suffer from severe sleep apnea. So i've been researching cpap machines etc and apparently Resmed AS 11 is the top rated CPAP on the market. So I just noticed that Resmed $RMD is #3 in the S&P top gainers today. It must be a sign....
View on StockTwits ↗
Four analysts moved on Dave & Buster's before Tuesday's open. Dennis Geiger of UBS and Lynne Collier of Freedom Capital both cut to nine dollars, under the twelve that was AnaChart's low on the name. Bender and Hickey reiterated. Nike and ResMed also drew notes. https://anachart.com/market-update/selected-stock-price-target-news-september-15-2026/ $PLAY $NKE $RMD
View on StockTwits ↗
$ACGL $RMD $STLD $CHT $CQP Arch Capital benefits from insurance pricing, ResMed benefits from sleep-health demand, Steel Dynamics benefits from steel and manufacturing activity, Chunghwa Telecom benefits from telecom demand, and Cheniere benefits from LNG exports and natural-gas markets. I'm watching insurance rates, medical-device adoption, steel prices, telecom growth, and LNG spreads.
View on StockTwits ↗
$RMD Though shaken by the market's overconcentration on GLP-1, it will ultimately go my way.
View on StockTwits ↗
$ACGL $RMD $STLD $CHT $CQP Arch Capital benefits from insurance pricing, ResMed benefits from sleep-health demand, Steel Dynamics benefits from steel and manufacturing activity, Chunghwa Telecom benefits from telecom demand, and Cheniere benefits from LNG exports and natural-gas markets. I'm watching insurance rates, medical-device adoption, steel prices, telecom growth, and LNG spreads.
View on StockTwits ↗
$RMD Price: $230.65 (+4.85%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.32% RSI: 68.5 | Momentum: Strong Momentum Volume: -34.9% vs avg Volatility: 2.48% Support: $190.21 | Resistance: $231.04 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
View on StockTwits ↗
$AAOI $ANET $ASML $RMD $ZETA $110 gap gotta fill
View on StockTwits ↗
$AAOI This one has an explosive look. > Recent correction was bought up at 200 Day SMA > Clearing the downtrend line > Back above 21EMA These are the signs you see but ignore And then chase 30% higher. $ASML $ZETA $ANET $RMD
View on StockTwits ↗
Recent Dividend Increases - Updated 08/14/26 https://www.dividendpower.org/dividend-increases/ $CSL $ITW $DOV $RMD $WGO
View on StockTwits ↗
$RMD 200P Sep 18 $212.1K · $2.11/contract · 6.8x Vol/OI Spot $219.55 RMD put flow $212K at 6.8x Vol/OI targets $197.89 breakeven in 39 DTE, requiring 9.9% drop from $219.55 spot.
View on StockTwits ↗
$RMD Strong demand for sleep-apnea devices📈
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.